URINARY PORTER-SILBER CHROMOGENS FOLLOWING INTRAVENOUS METHOPYRAPONE AND ACTH IN PATIENTS WITH BREAST CANCER.
D015065:17-Hydroxycorticosteroids; D000324:Adrenocorticotropic Hormone / Q000627:therapeutic use*; D001943:Breast Neoplasms; D004358:Drug Therapy; D005853:Geriatrics; D006801:Humans; D008408:Mastectomy; D008797:Metyrapone; D009362:Neoplasm Metastasis; D010600:Pharmacology; D010827:Physiology; D010860:Pigments, Biological; D010902:Pituitary Gland; D010912:Pituitary-Adrenal Function Tests; D013960:Thyroid Function Tests; D014556:Urine
D015065:17-Hydroxycorticosteroids; D010860:Pigments, Biological; C004835:Porter Silber chromogens; D000324:Adrenocorticotropic Hormone; D008797:Metyrapone
17-HYDROXYCORTICOSTEROIDS; BREAST NEOPLASMS; CORTICOTROPIN, THERAPEUTIC; DRUG THERAPY; GERIATRICS; MASTECTOMY; METYRAPONE; NEOPLASM METASTASIS; PHARMACOLOGY; PHYSIOLOGY; PIGMENTS; PITUITARY GLAND; PITUITARY-ADRENAL FUNCTION TESTS; THYROID GLAND FUNCTION TESTS; URINE